Diana S Osorio1, Jessica Hu2, Carole Mitchell3, Jeffrey C Allen3, Joseph Stanek1, Mari Hagiwara2, Matthias A Karajannis4. 1. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. 2. Division of Neuroradiology, Department of Radiology, NYU Langone Health, New York, NY, USA. 3. Department of Pediatrics, NYU Langone Health, New York, NY, USA. 4. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. karajanm@mskcc.org.
Abstract
INTRODUCTION: Epidermal growth factor receptors EGFR and ErbB2 are overexpressed in schwannomas and meningiomas. Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients. Its antitumor activity against meningiomas, however, is unknown. METHODS: We conducted a retrospective review of patients with NF2 and progressive vestibular schwannomas treated on a phase 2 clinical trial with lapatinib (NCT00973739). We included patients with at least one volumetrically measurable meningioma (> 0.5 cm3) who received at least five 28-day courses of treatment. Patients received lapatinib 1500 mg daily. Meningioma response was assessed using 3-dimensional MRI volumetrics. Progressive meningioma growth and response were defined as + 20 and - 20% change in tumor volume from baseline, respectively. Off-treatment was defined as any period > 5 months without lapatinib. RESULTS: Eight patients (ages: 20-58 years) who met criteria had 17 evaluable meningiomas with a combined volume of 61.35 cc at baseline, 61.17 cc during treatment, and 108.86 cc (+ 77.44% change) off-treatment, p = 0.0033. Median time on-treatment and off-treatment was 15.5 and 16.7 months, respectively. On-treatment mean and median annualized growth rates were 10.67 and 1.32%, respectively. Off-treatment mean and median annualized growth rates were 20.05 and 10.42%, respectively. The best volumetric response was - 26.1% after 23 months on lapatinib. Two tumors increased > 20% volumetrically on-treatment, compared to eight tumors off-treatment. CONCLUSIONS: These data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2 patients, and support prospective studies of lapatinib for NF2 patients with progressive meningiomas.
INTRODUCTION: Epidermal growth factor receptors EGFR and ErbB2 are overexpressed in schwannomas and meningiomas. Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients. Its antitumor activity against meningiomas, however, is unknown. METHODS: We conducted a retrospective review of patients with NF2 and progressive vestibular schwannomas treated on a phase 2 clinical trial with lapatinib (NCT00973739). We included patients with at least one volumetrically measurable meningioma (> 0.5 cm3) who received at least five 28-day courses of treatment. Patients received lapatinib 1500 mg daily. Meningioma response was assessed using 3-dimensional MRI volumetrics. Progressive meningioma growth and response were defined as + 20 and - 20% change in tumor volume from baseline, respectively. Off-treatment was defined as any period > 5 months without lapatinib. RESULTS: Eight patients (ages: 20-58 years) who met criteria had 17 evaluable meningiomas with a combined volume of 61.35 cc at baseline, 61.17 cc during treatment, and 108.86 cc (+ 77.44% change) off-treatment, p = 0.0033. Median time on-treatment and off-treatment was 15.5 and 16.7 months, respectively. On-treatment mean and median annualized growth rates were 10.67 and 1.32%, respectively. Off-treatment mean and median annualized growth rates were 20.05 and 10.42%, respectively. The best volumetric response was - 26.1% after 23 months on lapatinib. Two tumors increased > 20% volumetrically on-treatment, compared to eight tumors off-treatment. CONCLUSIONS: These data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2patients, and support prospective studies of lapatinib for NF2patients with progressive meningiomas.
Authors: B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch Journal: J Neurooncol Date: 1996-02 Impact factor: 4.130
Authors: J Kros; K de Greve; A van Tilborg; W Hop; H Pieterman; C Avezaat; R Lekanne Dit Deprez; E Zwarthoff Journal: J Pathol Date: 2001-07 Impact factor: 7.996
Authors: Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen Journal: J Neurooncol Date: 2009-06-28 Impact factor: 4.130
Authors: R Wellenreuther; J A Kraus; D Lenartz; A G Menon; J Schramm; D N Louis; V Ramesh; J F Gusella; O D Wiestler; A von Deimling Journal: Am J Pathol Date: 1995-04 Impact factor: 4.307
Authors: Amy J Chien; Julie A Illi; Andrew H Ko; Wolfgang M Korn; Lawrence Fong; Lee-may Chen; Mohammed Kashani-Sabet; Charles J Ryan; Jonathan E Rosenberg; Sarita Dubey; Eric J Small; Thierry M Jahan; Nola M Hylton; Benjamin M Yeh; Yong Huang; Kevin M Koch; Mark M Moasser Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Roberta L Beauchamp; Serkan Erdin; Luke Witt; Justin T Jordan; Scott R Plotkin; James F Gusella; Vijaya Ramesh Journal: J Biol Chem Date: 2020-12-09 Impact factor: 5.486